Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

11/15/2013 | 09:34pm US/Eastern
Recommend:
0

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664
carolyn@burzynskiclinic.com


© Business Wire 2013
Recommend :
0
React to this article
Latest news
Date Title
1m ago GRANITE CONSTRUCTION : Announces Timing of Earnings Release and Investor Conference Call
1m ago Patent Issued for X-Ray Method and X-Ray System for Merging X-Ray Images and Determining Three-Dimensional Volume Data
1m ago Patent Issued for Talar Implants and Methods of Use
1m ago Researchers Submit Patent Application, "Medical Workflow Determination and Optimization", for Approval
1m ago MEDTRONIC : Patent Issued for Therapy Programming Guidance Based on Stored Programming History
1m ago Researchers Submit Patent Application, "Adaptive Medical Documentation System", for Approval
1m ago SAMSUNG ELECTRO MECHANICS : Researchers Submit Patent Application, "Multilayer Ceramic Capacitor", for Approval
1m ago Researchers Submit Patent Application, "Medical Instrument, Medicine System and Method for Displaying the Position of a Position Marker", for Approval
2m ago VOLKSWAGEN : 2 House Dems pressing inquiry into Tenn. VW vote
3m ago FEDFIRST FINANCIAL : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of FedFirst Financial Corp. In Connection With the Sale of The Company
Latest news
Advertisement
Hot News 
MOLEX : EXTreme Ten60Power™ Split Blade, Delivering Greater Power Contact and Design Flexibility
BELGRAVIUM TECHNOLOGIES : Signs IT Contract With First Great Western
LDK SOLAR : Requests Review of NYSE Regulation's Decision to Suspend Trading and Commence Delisting Procedures
APRICUS BIOSCIENCES' : Partner in the United Kingdom Accepts First Shipment of Vitaros(R)
SNOOZEBOX : Shares Tumble As Losses Widen; Plans GBP11 Million Fundraising
Most Read News
8m ago BUSINESS MACHINES : IBM reports lowest quarterly revenue in 5 years as hardware sales fall
7m ago UNITED RENTALS : Announces First Quarter 2014 Results Reaffirms Full Year Outlook
7m ago LOJAS MARISA : Marisa opens new store in Paulo Afonso
8m ago CELANESE : Announces Vinyl Acetate-Based Emulsions Price Increase in Europe, Middle East and Africa
8m ago BAYLAKE CORP. : Declares Dividend and Extends Stock Repurchase Program
Most recommended articles
14h ago Global shares up on China relief, Ukraine strains remain
7h ago SPORTS DIRECT : FTSE advances on Chinese data, Sports Direct sprints ahead
6d agoDJCarrefour Sales Grow at Fastest Pace in Two Years
8m ago BUSINESS MACHINES : IBM reports lowest quarterly revenue in 5 years as hardware sales fall
13m agoDJGRAIN HIGHLIGHTS : Top Stories of the Day
Dynamic quotes  
ON
| OFF